VCs—particularly those in Europe—love pre-cooked start-ups and one of the best places to find them is within Big Pharma. So it wasn’t that surprising to see Belgium-based Movetis NV raise a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson . [See Deal] The round—led by Sofinnova Partners and Life Sciences Partners—overshadows all of 2006’s drug discovery Series As and confirms investors’ continued appetite for lower-risk, closer-to-market ventures. (Another Johnson & Johnson offshoot, delivery firm Macroflux Corp., raised $75 million in October 2006 [See Deal].) A smaller round for Movetis was originally planned, notes Antoine Papiernik, managing partner at Sofinnova, but "demand was so big that we pushed it up." (See "The A List: 2006’s Trend-Shaping Series A Financings," START-UP, January 2007 Also see "The A-List: 2006's Trend-Shaping Series A Financings" - Scrip, 1 January, 2007..)
Movetis Takes GI from J&J
VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."